Latest bladder cancer Stories
Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in Patients with Lower Performance Status Phase
Studies show NBI visualizes Non-Muscle-Invasive Bladder Cancer (NMIBC) lesions in additional 17 percent of patients and 24 percent additional tumors - a turning point for identifying the costly, recurrent
Studies Find Potentially Predictive Biomarkers May Lead to Better Patient Outcomes, Bladder Cancer Treatment Options Extend Beyond Chemotherapy Milwaukee, WI
Presentations at SABCS and SUO Reveal Company's Ability to Detect Breast and Bladder Cancers in Blood and Urine, Respectively SAN ANTONIO, Dec.
Sonatherm® Laparoscopic HIFU device used to demonstrate thermal ablation at hands-on lab Charlotte, NC (PRWEB) November 25, 2014 SonaCare Medical,
OWINGS MILLS, Md., Nov.
These Studies and Genomic Health's First Liquid Biopsy Study in Bladder Cancer To Be Presented at 2014 Society of Urologic Oncology Annual Meeting, December 3-5 REDWOOD CITY, Calif., Nov.
Another Actos Lawsuit Purports Patient Develop Bladder Cancer After Taking The Type Two Diabetes Medication Columbus, OH (PRWEB) October 18, 2014 Wright
The Philadelphia jury awarded the man $2 million: Actos was deemed a contributing factor to the man’s bladder cancer, Takeda was found to have not warned physicians concerning the drug’s cancer
- A trick or prank.